CVS Health (CVS) PT Trimmed to $110 at Credit Suisse
- Target (TGT) November/December Comps Fell 1.3%; Lowers Guidance
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Credit Suisse analyst Robert Willoughby trimmed his price target on CVS Health (NYSE: CVS) to $110.00 (from $115.00) but maintained an Outperform rating after news the US Department of Defense military health program, announced that as of December 1, CVS will no longer be a part of its pharmacy network, replaced by competitor Walgreens.
Willoughby commented, "CVS was on the winning side of a 2011 dispute between Express Scripts and Walgreens that saw Walgreens removed from TRICARE's pharmacy network. The news is consistent with recent efforts by Walgreens to align itself more with payors to gain more pharmacy market share, curbing CVS's opportunity."
The firm is lowering 2017 EPS estimate to $6.55 (from $6.60) on a weaker revenue outlook.
Shares of CVS Health closed at $88.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades J. C. Penney (JCP) to Underperform, Says Limited Topline Opportunities Delay Turnaround
- BMO Capital Downgrades Walt Disney (DIS) to Underperform; Too Early to Own for FY18
- Morgan Stanley Downgrades Verisk Analytics (VRSK) to Equalweight
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesCredit Suisse, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!